Showing 11-20 of 21 results for "".
- With New Team, Revance Readies for Launch of their Botox Competitorhttps://practicaldermatology.com/news/with-new-team-revance-readies-for-launch-of-their-botox-competitor/2457819/With the advent of four new positions, Revance Therapeutics is expanding their commercialization team in anticipation of the product launch of for DaxibotulinumtoxinA for Injection (RT002) in the treatment of glabellar lines. Dustin Sjuts is the new Vice President of Strategy and Sales, Aestheti…
- Dermavant Submits Supplemental NDA for VTAMA (tapinarof) Cream, 1% for Atopic Dermatitishttps://practicaldermatology.com/news/dermavant-submits-supplemental-nda-for-vtama-tapinarof-1-cream/2462242/Dermavant announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VTAMA (tapinarof) cream, 1% for treating atopic dermatitis (AD) in adults and children aged 2 years and older. The novel, aryl hydrocarbon receptor antagonist is…
- Dermavant Completes Enrollment for Long-Term Safety Study of Tapinarof in Adult Psoriasishttps://practicaldermatology.com/news/dermavant-completes-enrollment-for-long-term-safety-study-of-tapinarof-in-adult-psoriasis/2460416/Patient enrollment in Dermavant’s long-term safety study of tapinarof is now complete, the company says. Tapinarof is a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) being investigated for use in adult patients diagnosed with plaque psori…
- Galderma Receives FDA Approval for Epiduo Forte for Acnehttps://practicaldermatology.com/news/galderma-receives-fda-approval-for-epiduo-forte-for-acne/2458909/The FDA approved Galderma’s antibiotic-free Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%, for the once-daily, topical treatment of acne vulgaris. Epiduo Forte Gel is the first combination of these strengths of the retinoid, adapalene, and benzoyl peroxide, developed for the moderat…
- Eye on the AD Pipeline: Dermavant Completes Enrollment of Phase 3 Trials of VTAMA in Adults and Children with ADhttps://practicaldermatology.com/news/eye-on-the-ad-pipeline-dermavant-completes-enrollment-of-phase-3-trials-of-vtama-in-adults-and-children-with-ad/2461561/Dermavant Sciences has completed patient enrollment in its ADORING 1 and 2 Phase 3 clinical trials of VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children as young as 2 years old. VTAMA cream is a novel, aryl hydrocarbon receptor agonist, in develo…
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class. Dermavant says it will have product available in…
- FDA Accepts Dermavant's NDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-dermavants-nda-for-tapinarof-cream-for-the-treatment-of-adults-with-plaque-psoriasis/2460886/The FDA has accepted Dermavant Sciences' New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically e…
- Dermavant: Promising Interim Analysis from Third Phase 3 Trial for Tapinarof in Psoriasishttps://practicaldermatology.com/news/dermavant-promising-interim-analysis-from-third-phase-3-trial-for-tapinarof-in-psoriasis/2460693/Positive results from a planned interim analysis of PSOARING 3, Dermavant Sciences’ long-term, open-label safety study, show that approximately 40 percent of subjects treated with investigational tapinarof cream, 1% achieved complete disease clearance (PGA score = 0). Treatment was well tolerated a…
- Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for Psoriasishttps://practicaldermatology.com/news/dermavant-completes-patient-enrollment-for-two-phase-3-clinical-trials-of-tapinarof-for-psoriasis/2460339/Dermavant Sciences completed patient enrollment in PSOARING 1 and PSOARING 2 clinical trials of tapinarof, a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA), in adult patients diagnosed with plaque psoriasis. Dermavant expects to announce …
- VTAMA (Tapinarof) Cream, 1% Shows Efficacy in Patients With Intertriginous Plaque Psoriasishttps://practicaldermatology.com/news/vtama-tapinarof-cream-1/2462085/VTAMA (tapinarof) Cream, 1% performed well in intertriginous plaque psoriasis (iPsO), according to new Phase 4 data presented at the 43rd Annual Fall Clinical Dermatology Conference in Las Vegas. This Phase 4 study expands the body of data for VTAMA cream in adult plaque psoriasis. In the two 12-w…